In December 2021, the US Food and Drug Administration (FDA) approved Tezspire (tezepelumab-ekko; Amgen, Inc and AstraZeneca AB), a thymic stromal lymphopoietin (TSLP) blocker, for the add-on ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the US. TEZSPIRE was approved by the US Food and ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved tezepelumab-ekko for self-administration in a prefilled, single-use pen among patients aged ...

TEZSPIRE is currently approved for the treatment of severe asthma in the U.S., Europe, Japan, and more than 50 countries across the globe. 22-25 It is approved as a pre-filled, single-use pen and auto ...

(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) Wednesday said its Tezspire (tezepelumab) has been approved in the European Union for the treatment of severe asthma. Tezspire is approved ...

U.K.'s National Institute for Clinical Excellence (NICE) in its final draft guidance recommended Amgen (NASDAQ:AMGN) and AstraZeneca's (NASDAQ:AZN) asthma therapy Tezspire for use in the National ...

Aiolos Bio launched with a $245 million series A investment to advance its novel, Phase 2-ready antibody for treating asthma, the firm said earlier this week. The biotech startup is aiming to best ...

WILMINGTON, Del.--(BUSINESS WIRE)--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (tezepelumab) as a potential treatment for chronic obstructive pulmonary disorder (COPD), the companies are touting the ...

THOUSAND OAKS, Calif., Jan. 13, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S. TEZSPIRE ...